China Expects $19 Billion Pharma Output By 2000

16 July 1995

Director-general of China's State Administration of Medicines Zheng Xiaoyu has told the China Foreign Trade Journal that at the end of the current decade China's pharmaceutical industry will have an annual output value of 160 billion renminbi ($19.28 billion), with annual imports and exports worth $6 billion, rising by 10% a year.

He added that, in 1994, Chinese pharmaceutical companies supplied products for export to foreign trading companies worth 12 billion renminbi, which is an increase of 50% on 1993.

On the participation of foreign companies in China's pharmaceutical industry, the official said that the principle of setting up new companies is that they develop new products, have new production techniques and are export-oriented. This emphasis on producing new products is a result of fierce competition on the international drugs market, and Mr Xiaoyu called for efforts to be made to support new products with new funds. In addition, sales of quality products produced by state enterprises should be increased.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight